Arbutus Biopharma Corporation

NASDAQ:ABUS

Biotechnology

Healthcare
$4.11 +1.13%

+$0.05 today

Market cap
$630.03M
Beta
0.63
P/E (TTM)
5.4
EPS (TTM)
$0.83
52W Low $3.04High $5.10

Volume 2.90M

Average 1.76M

ABUS Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Arbutus Biopharma CorporationNASDAQ: ABUS

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $11K fell 96.7% year over year, behind the -21.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 98.9% from the prior quarter. Over 3 fiscal years it compounded at -36.6% a year.

Context

  • Depreciation & amortization amounted to 2.6% of revenue in FY2025, down 19.8 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -96.7% toward the trailing-twelve-month pace of -21.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$11K-98.9% QoQ
Last fiscal yearDec 2025
$363K-73.7% YoY
LTMMar 2026
$1.07M-21.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-96.7%——
1 year-73.7%——
3-year CAGR-36.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
363K USD
Year-over-year change
-73.7%
4-year CAGR
-32.5%

Depreciation & Amortization vs competitors

How ABUS compares with its peers on the latest reported figures

  • ABUS's LTM Mar 2026 depreciation & amortization of $1.07M is the 5th largest of the 9 companies compared; the peer median is $2.92M.
  • Its year-over-year change of -21.3% is the lowest of 8, against a peer median of +11.3%.
  • Depreciation & amortization amounts to 0.6% of revenue for ABUS, versus a peer median of 6.5%.
ABUS Competitors Peer median
Depreciation & Amortization for ABUS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$54.76M -3.1%+7.8%1.1%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$26.62M +11.3%+28.7%5.9%
VIRVir Biotechnology, Inc.LTM Mar 2026$18.23M +41.3%+46.1%27.8%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$4.95M +56.5%+19.6%7.2%
ABUSArbutus Biopharma CorporationLTM Mar 2026$1.07M -21.3%-36.6%0.6%
SLNSilence Therapeutics plcLTM Mar 2026$885K —-2.3%96.0%
BNTCBenitec Biopharma Inc.LTM Mar 2026$475K +28.7%+0.3%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$416K +0.0%+17.0%—
ASMBAssembly Biosciences, Inc.LTM Mar 2026$122K -6.2%-36.3%0.2%
Peer median (excluding ABUS) $2.92M+11.3%+12.4%6.5%

Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(76.25M)(69.46M)(72.85M)(69.92M)(33.5M)
Depreciation & Amortization1.75M1.43M1.4M1.38M363K
Deferred Income Tax(8.18M)0000
Stock-Based Compensation6.42M7.18M9.3M8.99M6.95M
Change in Working Capital930K29.24M(18.23M)(2.83M)(10.02M)
Accounts Receivables413K(453K)(424K)(633K)1.38M
Inventory(1.91M)0000
Accounts Payables1.91M5.22M00(2.11M)
Other Working Capital517K24.48M(17.81M)(2.2M)(9.29M)
Other Non-Cash Items7.79M(3.75M)(5.56M)(2.47M)(3.43M)
Operating Cash Flow(67.53M)(35.36M)(85.94M)(64.85M)(39.64M)
Capital Expenditures(809K)(512K)(1.01M)(182K)0
Acquisitions (Net)1.81M0000
Purchases of Investments(82.22M)(130.43M)(80.51M)(141.51M)12.87M
Sales of Investments70.35M56M132.27M164.64M155.28M
Other Investing Activities(1.81M)020K0(152.56M)
Investing Cash Flow(12.68M)(74.94M)50.77M22.95M15.58M
Debt Repayment00000
Common Stock Issued134.67M20.32M29.85M44.12M5.72M
Common Stock Repurchased00000
Dividends Paid(12.14M)0000
Other Financing Activities14.71M11.49M795K7.87M0
Financing Cash Flow137.24M31.81M30.65M52M5.72M
Effect of Forex Changes5K(22K)25K(49K)14K
Net Change in Cash57.03M(78.51M)(4.49M)10.05M(18.32M)
Free Cash Flow(68.34M)(35.87M)(86.94M)(65.03M)(39.64M)

Arbutus Biopharma Corporation

NASDAQ:ABUS

Intrinsic Alpha fair value

Locked

Current Price

$4.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.